Global Gemcitabine Market

Gemcitabine Comprehensive Study by Application (Pancreas Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Soft-Tissue Sarcoma, Metastatic Breast Cancer, Ovarian Cancer), Distribution Channel (Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy), Dose of Gemcitabine (0.2g, 1.0g, 2.0g) Players and Region - Global Market Outlook to 2030

Gemcitabine Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Gemcitabine is an anti-cancer and cytosine analogue, chemotherapy drug. Gemcitabine is classified as an intravenously administered antimetabolite agent used in the therapy of several forms of advanced, pancreatic, lung, breast, ovarian and bladder cancer. Gemcitabine is associated with a high rate of transient serum enzyme elevations during therapy but is a very rare cause of acute, clinically apparent liver injury.

Highlights from Gemcitabine Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.0%


The key Players profiled in the report are Pfizer (United States), Sun Pharma (India), Tapi Teva (Israel), Eli Lilly and Company (United States), Shanghai China Industrial Co., Ltd (China), Jinkang Pharmaceutical Technology (China), Fresenius Kabi Oncology Limited (India), Arch Pharmalabs (India), Bharat Pharmaceuticals (India) and Haisco Pharmaceutical Group (China). Additionally, other players that are part of this comprehensive study are Ningbo Menovo Pharmaceutical (China), ScinoPharm (Taiwan), HISUN USA, Inc. (United States) and Wuhu Huaren Science and Technology (China).

Geographic Breakdown and Segment Analysis
The Global Gemcitabine market presents a comprehensive analysis of the Gemcitabine market by end-user/application (Pancreas Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Soft-Tissue Sarcoma, Metastatic Breast Cancer and Ovarian Cancer), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Gemcitabine industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Gemcitabine market

Analyst at AMA have segmented the market study of Global Gemcitabine market by Type, Application and Region.

Influencing Trend:
Increasing Investment in Research & Development Globally

Market Growth Drivers:
Increasing Incidence of Ovarian Cancer and Rising Healthcare Expenditure and Government Funding

Challenges:
High Cost of Drug Development

Restraints:
Availability of Generic Drugs and Patent Expiration of Branded Drugs and Issue related to adverse Effects Associated with the use of Gemcitabine

Opportunities:
Rising Demand from Emerging Countries and Increase in Purchasing Power of Developing Countries

Market Developments Activities:
In December 12, 2023, Teva Pharmaceuticals and Celltrion Healthcare announced a collaboration to commercialize Celltrion's biosimilar version of Gemcitabine in Europe.
In August 2023, Teva Pharmaceuticals announces the launch of a new generic version of Gemcitabine injection in the United States.



The competitive landscape for gemcitabine is expected to remain challenging in the coming years. However, the drug is still widely used and is likely to remain an important treatment option for many cancer patients.

Key Target Audience
Manufacturers of Gemcitabine, Suppliers of Gemcitabine, Wholesalers, Distributors and Retailers of Gemcitabine, Healthcare Industry, Pharmaceutical Industry, Medical Research Laboratories, Academic Research Institutes, Regulatory Bodies and Governmental Bodies

Report Objectives / Segmentation Covered

By Application
  • Pancreas Cancer
  • Non-Small Cell Lung Cancer
  • Bladder Cancer
  • Soft-Tissue Sarcoma
  • Metastatic Breast Cancer
  • Ovarian Cancer
By Distribution Channel
  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

By Dose of Gemcitabine
  • 0.2g
  • 1.0g
  • 2.0g

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Ovarian Cancer
      • 3.2.2. Rising Healthcare Expenditure and Government Funding
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Drug Development
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in Research & Development Globally
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gemcitabine, by Application, Distribution Channel, Dose of Gemcitabine and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gemcitabine (Value)
      • 5.2.1. Global Gemcitabine by: Application (Value)
        • 5.2.1.1. Pancreas Cancer
        • 5.2.1.2. Non-Small Cell Lung Cancer
        • 5.2.1.3. Bladder Cancer
        • 5.2.1.4. Soft-Tissue Sarcoma
        • 5.2.1.5. Metastatic Breast Cancer
        • 5.2.1.6. Ovarian Cancer
      • 5.2.2. Global Gemcitabine by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Drug Store
        • 5.2.2.3. Specialty Pharmacy
        • 5.2.2.4. E-Pharmacy
      • 5.2.3. Global Gemcitabine by: Dose of Gemcitabine (Value)
        • 5.2.3.1. 0.2g
        • 5.2.3.2. 1.0g
        • 5.2.3.3. 2.0g
      • 5.2.4. Global Gemcitabine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Gemcitabine (Volume)
      • 5.3.1. Global Gemcitabine by: Application (Volume)
        • 5.3.1.1. Pancreas Cancer
        • 5.3.1.2. Non-Small Cell Lung Cancer
        • 5.3.1.3. Bladder Cancer
        • 5.3.1.4. Soft-Tissue Sarcoma
        • 5.3.1.5. Metastatic Breast Cancer
        • 5.3.1.6. Ovarian Cancer
      • 5.3.2. Global Gemcitabine by: Distribution Channel (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Drug Store
        • 5.3.2.3. Specialty Pharmacy
        • 5.3.2.4. E-Pharmacy
      • 5.3.3. Global Gemcitabine by: Dose of Gemcitabine (Volume)
        • 5.3.3.1. 0.2g
        • 5.3.3.2. 1.0g
        • 5.3.3.3. 2.0g
      • 5.3.4. Global Gemcitabine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Gemcitabine (Price)
  • 6. Gemcitabine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sun Pharma (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Tapi Teva (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shanghai China Industrial Co., Ltd (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Jinkang Pharmaceutical Technology (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius Kabi Oncology Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Arch Pharmalabs (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bharat Pharmaceuticals (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Haisco Pharmaceutical Group (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gemcitabine Sale, by Application, Distribution Channel, Dose of Gemcitabine and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gemcitabine (Value)
      • 7.2.1. Global Gemcitabine by: Application (Value)
        • 7.2.1.1. Pancreas Cancer
        • 7.2.1.2. Non-Small Cell Lung Cancer
        • 7.2.1.3. Bladder Cancer
        • 7.2.1.4. Soft-Tissue Sarcoma
        • 7.2.1.5. Metastatic Breast Cancer
        • 7.2.1.6. Ovarian Cancer
      • 7.2.2. Global Gemcitabine by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Drug Store
        • 7.2.2.3. Specialty Pharmacy
        • 7.2.2.4. E-Pharmacy
      • 7.2.3. Global Gemcitabine by: Dose of Gemcitabine (Value)
        • 7.2.3.1. 0.2g
        • 7.2.3.2. 1.0g
        • 7.2.3.3. 2.0g
      • 7.2.4. Global Gemcitabine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Gemcitabine (Volume)
      • 7.3.1. Global Gemcitabine by: Application (Volume)
        • 7.3.1.1. Pancreas Cancer
        • 7.3.1.2. Non-Small Cell Lung Cancer
        • 7.3.1.3. Bladder Cancer
        • 7.3.1.4. Soft-Tissue Sarcoma
        • 7.3.1.5. Metastatic Breast Cancer
        • 7.3.1.6. Ovarian Cancer
      • 7.3.2. Global Gemcitabine by: Distribution Channel (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Drug Store
        • 7.3.2.3. Specialty Pharmacy
        • 7.3.2.4. E-Pharmacy
      • 7.3.3. Global Gemcitabine by: Dose of Gemcitabine (Volume)
        • 7.3.3.1. 0.2g
        • 7.3.3.2. 1.0g
        • 7.3.3.3. 2.0g
      • 7.3.4. Global Gemcitabine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Gemcitabine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gemcitabine: by Application(USD Million)
  • Table 2. Gemcitabine Pancreas Cancer , by Region USD Million (2018-2023)
  • Table 3. Gemcitabine Non-Small Cell Lung Cancer , by Region USD Million (2018-2023)
  • Table 4. Gemcitabine Bladder Cancer , by Region USD Million (2018-2023)
  • Table 5. Gemcitabine Soft-Tissue Sarcoma , by Region USD Million (2018-2023)
  • Table 6. Gemcitabine Metastatic Breast Cancer , by Region USD Million (2018-2023)
  • Table 7. Gemcitabine Ovarian Cancer , by Region USD Million (2018-2023)
  • Table 8. Gemcitabine: by Distribution Channel(USD Million)
  • Table 9. Gemcitabine Hospitals , by Region USD Million (2018-2023)
  • Table 10. Gemcitabine Drug Store , by Region USD Million (2018-2023)
  • Table 11. Gemcitabine Specialty Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Gemcitabine E-Pharmacy , by Region USD Million (2018-2023)
  • Table 13. Gemcitabine: by Dose of Gemcitabine(USD Million)
  • Table 14. Gemcitabine 0.2g , by Region USD Million (2018-2023)
  • Table 15. Gemcitabine 1.0g , by Region USD Million (2018-2023)
  • Table 16. Gemcitabine 2.0g , by Region USD Million (2018-2023)
  • Table 17. South America Gemcitabine, by Country USD Million (2018-2023)
  • Table 18. South America Gemcitabine, by Application USD Million (2018-2023)
  • Table 19. South America Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 20. South America Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 21. Brazil Gemcitabine, by Application USD Million (2018-2023)
  • Table 22. Brazil Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 23. Brazil Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 24. Argentina Gemcitabine, by Application USD Million (2018-2023)
  • Table 25. Argentina Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 27. Rest of South America Gemcitabine, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 29. Rest of South America Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 30. Asia Pacific Gemcitabine, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Gemcitabine, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 33. Asia Pacific Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 34. China Gemcitabine, by Application USD Million (2018-2023)
  • Table 35. China Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 36. China Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 37. Japan Gemcitabine, by Application USD Million (2018-2023)
  • Table 38. Japan Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 39. Japan Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 40. India Gemcitabine, by Application USD Million (2018-2023)
  • Table 41. India Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 42. India Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 43. South Korea Gemcitabine, by Application USD Million (2018-2023)
  • Table 44. South Korea Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 45. South Korea Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 46. Taiwan Gemcitabine, by Application USD Million (2018-2023)
  • Table 47. Taiwan Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 48. Taiwan Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 49. Australia Gemcitabine, by Application USD Million (2018-2023)
  • Table 50. Australia Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 51. Australia Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Gemcitabine, by Application USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 55. Europe Gemcitabine, by Country USD Million (2018-2023)
  • Table 56. Europe Gemcitabine, by Application USD Million (2018-2023)
  • Table 57. Europe Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 58. Europe Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 59. Germany Gemcitabine, by Application USD Million (2018-2023)
  • Table 60. Germany Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 61. Germany Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 62. France Gemcitabine, by Application USD Million (2018-2023)
  • Table 63. France Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 64. France Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 65. Italy Gemcitabine, by Application USD Million (2018-2023)
  • Table 66. Italy Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 67. Italy Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 68. United Kingdom Gemcitabine, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 70. United Kingdom Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 71. Netherlands Gemcitabine, by Application USD Million (2018-2023)
  • Table 72. Netherlands Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 73. Netherlands Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 74. Rest of Europe Gemcitabine, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 76. Rest of Europe Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 77. MEA Gemcitabine, by Country USD Million (2018-2023)
  • Table 78. MEA Gemcitabine, by Application USD Million (2018-2023)
  • Table 79. MEA Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 80. MEA Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 81. Middle East Gemcitabine, by Application USD Million (2018-2023)
  • Table 82. Middle East Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 83. Middle East Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 84. Africa Gemcitabine, by Application USD Million (2018-2023)
  • Table 85. Africa Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 86. Africa Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 87. North America Gemcitabine, by Country USD Million (2018-2023)
  • Table 88. North America Gemcitabine, by Application USD Million (2018-2023)
  • Table 89. North America Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 90. North America Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 91. United States Gemcitabine, by Application USD Million (2018-2023)
  • Table 92. United States Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 93. United States Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 94. Canada Gemcitabine, by Application USD Million (2018-2023)
  • Table 95. Canada Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 96. Canada Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 97. Mexico Gemcitabine, by Application USD Million (2018-2023)
  • Table 98. Mexico Gemcitabine, by Distribution Channel USD Million (2018-2023)
  • Table 99. Mexico Gemcitabine, by Dose of Gemcitabine USD Million (2018-2023)
  • Table 100. Gemcitabine Sales: by Application(K Units)
  • Table 101. Gemcitabine Sales Pancreas Cancer , by Region K Units (2018-2023)
  • Table 102. Gemcitabine Sales Non-Small Cell Lung Cancer , by Region K Units (2018-2023)
  • Table 103. Gemcitabine Sales Bladder Cancer , by Region K Units (2018-2023)
  • Table 104. Gemcitabine Sales Soft-Tissue Sarcoma , by Region K Units (2018-2023)
  • Table 105. Gemcitabine Sales Metastatic Breast Cancer , by Region K Units (2018-2023)
  • Table 106. Gemcitabine Sales Ovarian Cancer , by Region K Units (2018-2023)
  • Table 107. Gemcitabine Sales: by Distribution Channel(K Units)
  • Table 108. Gemcitabine Sales Hospitals , by Region K Units (2018-2023)
  • Table 109. Gemcitabine Sales Drug Store , by Region K Units (2018-2023)
  • Table 110. Gemcitabine Sales Specialty Pharmacy , by Region K Units (2018-2023)
  • Table 111. Gemcitabine Sales E-Pharmacy , by Region K Units (2018-2023)
  • Table 112. Gemcitabine Sales: by Dose of Gemcitabine(K Units)
  • Table 113. Gemcitabine Sales 0.2g , by Region K Units (2018-2023)
  • Table 114. Gemcitabine Sales 1.0g , by Region K Units (2018-2023)
  • Table 115. Gemcitabine Sales 2.0g , by Region K Units (2018-2023)
  • Table 116. South America Gemcitabine Sales, by Country K Units (2018-2023)
  • Table 117. South America Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 118. South America Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 119. South America Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 120. Brazil Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 121. Brazil Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 122. Brazil Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 123. Argentina Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 124. Argentina Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 125. Argentina Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 126. Rest of South America Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 127. Rest of South America Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 128. Rest of South America Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 129. Asia Pacific Gemcitabine Sales, by Country K Units (2018-2023)
  • Table 130. Asia Pacific Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 131. Asia Pacific Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 132. Asia Pacific Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 133. China Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 134. China Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 135. China Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 136. Japan Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 137. Japan Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 138. Japan Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 139. India Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 140. India Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 141. India Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 142. South Korea Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 143. South Korea Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 144. South Korea Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 145. Taiwan Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 146. Taiwan Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 147. Taiwan Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 148. Australia Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 149. Australia Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 150. Australia Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 151. Rest of Asia-Pacific Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 152. Rest of Asia-Pacific Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 153. Rest of Asia-Pacific Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 154. Europe Gemcitabine Sales, by Country K Units (2018-2023)
  • Table 155. Europe Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 156. Europe Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 157. Europe Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 158. Germany Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 159. Germany Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 160. Germany Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 161. France Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 162. France Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 163. France Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 164. Italy Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 165. Italy Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 166. Italy Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 167. United Kingdom Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 168. United Kingdom Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 169. United Kingdom Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 170. Netherlands Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 171. Netherlands Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 172. Netherlands Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 173. Rest of Europe Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 174. Rest of Europe Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 175. Rest of Europe Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 176. MEA Gemcitabine Sales, by Country K Units (2018-2023)
  • Table 177. MEA Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 178. MEA Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 179. MEA Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 180. Middle East Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 181. Middle East Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 182. Middle East Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 183. Africa Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 184. Africa Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 185. Africa Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 186. North America Gemcitabine Sales, by Country K Units (2018-2023)
  • Table 187. North America Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 188. North America Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 189. North America Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 190. United States Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 191. United States Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 192. United States Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 193. Canada Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 194. Canada Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 195. Canada Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 196. Mexico Gemcitabine Sales, by Application K Units (2018-2023)
  • Table 197. Mexico Gemcitabine Sales, by Distribution Channel K Units (2018-2023)
  • Table 198. Mexico Gemcitabine Sales, by Dose of Gemcitabine K Units (2018-2023)
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Gemcitabine: by Application(USD Million)
  • Table 210. Gemcitabine Pancreas Cancer , by Region USD Million (2025-2030)
  • Table 211. Gemcitabine Non-Small Cell Lung Cancer , by Region USD Million (2025-2030)
  • Table 212. Gemcitabine Bladder Cancer , by Region USD Million (2025-2030)
  • Table 213. Gemcitabine Soft-Tissue Sarcoma , by Region USD Million (2025-2030)
  • Table 214. Gemcitabine Metastatic Breast Cancer , by Region USD Million (2025-2030)
  • Table 215. Gemcitabine Ovarian Cancer , by Region USD Million (2025-2030)
  • Table 216. Gemcitabine: by Distribution Channel(USD Million)
  • Table 217. Gemcitabine Hospitals , by Region USD Million (2025-2030)
  • Table 218. Gemcitabine Drug Store , by Region USD Million (2025-2030)
  • Table 219. Gemcitabine Specialty Pharmacy , by Region USD Million (2025-2030)
  • Table 220. Gemcitabine E-Pharmacy , by Region USD Million (2025-2030)
  • Table 221. Gemcitabine: by Dose of Gemcitabine(USD Million)
  • Table 222. Gemcitabine 0.2g , by Region USD Million (2025-2030)
  • Table 223. Gemcitabine 1.0g , by Region USD Million (2025-2030)
  • Table 224. Gemcitabine 2.0g , by Region USD Million (2025-2030)
  • Table 225. South America Gemcitabine, by Country USD Million (2025-2030)
  • Table 226. South America Gemcitabine, by Application USD Million (2025-2030)
  • Table 227. South America Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 228. South America Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 229. Brazil Gemcitabine, by Application USD Million (2025-2030)
  • Table 230. Brazil Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 231. Brazil Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 232. Argentina Gemcitabine, by Application USD Million (2025-2030)
  • Table 233. Argentina Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 234. Argentina Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 235. Rest of South America Gemcitabine, by Application USD Million (2025-2030)
  • Table 236. Rest of South America Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 237. Rest of South America Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 238. Asia Pacific Gemcitabine, by Country USD Million (2025-2030)
  • Table 239. Asia Pacific Gemcitabine, by Application USD Million (2025-2030)
  • Table 240. Asia Pacific Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 241. Asia Pacific Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 242. China Gemcitabine, by Application USD Million (2025-2030)
  • Table 243. China Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 244. China Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 245. Japan Gemcitabine, by Application USD Million (2025-2030)
  • Table 246. Japan Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 247. Japan Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 248. India Gemcitabine, by Application USD Million (2025-2030)
  • Table 249. India Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 250. India Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 251. South Korea Gemcitabine, by Application USD Million (2025-2030)
  • Table 252. South Korea Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 253. South Korea Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 254. Taiwan Gemcitabine, by Application USD Million (2025-2030)
  • Table 255. Taiwan Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 256. Taiwan Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 257. Australia Gemcitabine, by Application USD Million (2025-2030)
  • Table 258. Australia Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 259. Australia Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 260. Rest of Asia-Pacific Gemcitabine, by Application USD Million (2025-2030)
  • Table 261. Rest of Asia-Pacific Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 262. Rest of Asia-Pacific Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 263. Europe Gemcitabine, by Country USD Million (2025-2030)
  • Table 264. Europe Gemcitabine, by Application USD Million (2025-2030)
  • Table 265. Europe Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 266. Europe Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 267. Germany Gemcitabine, by Application USD Million (2025-2030)
  • Table 268. Germany Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 269. Germany Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 270. France Gemcitabine, by Application USD Million (2025-2030)
  • Table 271. France Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 272. France Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 273. Italy Gemcitabine, by Application USD Million (2025-2030)
  • Table 274. Italy Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 275. Italy Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 276. United Kingdom Gemcitabine, by Application USD Million (2025-2030)
  • Table 277. United Kingdom Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 278. United Kingdom Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 279. Netherlands Gemcitabine, by Application USD Million (2025-2030)
  • Table 280. Netherlands Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 281. Netherlands Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 282. Rest of Europe Gemcitabine, by Application USD Million (2025-2030)
  • Table 283. Rest of Europe Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 284. Rest of Europe Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 285. MEA Gemcitabine, by Country USD Million (2025-2030)
  • Table 286. MEA Gemcitabine, by Application USD Million (2025-2030)
  • Table 287. MEA Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 288. MEA Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 289. Middle East Gemcitabine, by Application USD Million (2025-2030)
  • Table 290. Middle East Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 291. Middle East Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 292. Africa Gemcitabine, by Application USD Million (2025-2030)
  • Table 293. Africa Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 294. Africa Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 295. North America Gemcitabine, by Country USD Million (2025-2030)
  • Table 296. North America Gemcitabine, by Application USD Million (2025-2030)
  • Table 297. North America Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 298. North America Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 299. United States Gemcitabine, by Application USD Million (2025-2030)
  • Table 300. United States Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 301. United States Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 302. Canada Gemcitabine, by Application USD Million (2025-2030)
  • Table 303. Canada Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 304. Canada Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 305. Mexico Gemcitabine, by Application USD Million (2025-2030)
  • Table 306. Mexico Gemcitabine, by Distribution Channel USD Million (2025-2030)
  • Table 307. Mexico Gemcitabine, by Dose of Gemcitabine USD Million (2025-2030)
  • Table 308. Gemcitabine Sales: by Application(K Units)
  • Table 309. Gemcitabine Sales Pancreas Cancer , by Region K Units (2025-2030)
  • Table 310. Gemcitabine Sales Non-Small Cell Lung Cancer , by Region K Units (2025-2030)
  • Table 311. Gemcitabine Sales Bladder Cancer , by Region K Units (2025-2030)
  • Table 312. Gemcitabine Sales Soft-Tissue Sarcoma , by Region K Units (2025-2030)
  • Table 313. Gemcitabine Sales Metastatic Breast Cancer , by Region K Units (2025-2030)
  • Table 314. Gemcitabine Sales Ovarian Cancer , by Region K Units (2025-2030)
  • Table 315. Gemcitabine Sales: by Distribution Channel(K Units)
  • Table 316. Gemcitabine Sales Hospitals , by Region K Units (2025-2030)
  • Table 317. Gemcitabine Sales Drug Store , by Region K Units (2025-2030)
  • Table 318. Gemcitabine Sales Specialty Pharmacy , by Region K Units (2025-2030)
  • Table 319. Gemcitabine Sales E-Pharmacy , by Region K Units (2025-2030)
  • Table 320. Gemcitabine Sales: by Dose of Gemcitabine(K Units)
  • Table 321. Gemcitabine Sales 0.2g , by Region K Units (2025-2030)
  • Table 322. Gemcitabine Sales 1.0g , by Region K Units (2025-2030)
  • Table 323. Gemcitabine Sales 2.0g , by Region K Units (2025-2030)
  • Table 324. South America Gemcitabine Sales, by Country K Units (2025-2030)
  • Table 325. South America Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 326. South America Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 327. South America Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 328. Brazil Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 329. Brazil Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 330. Brazil Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 331. Argentina Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 332. Argentina Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 333. Argentina Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 334. Rest of South America Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 335. Rest of South America Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 336. Rest of South America Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 337. Asia Pacific Gemcitabine Sales, by Country K Units (2025-2030)
  • Table 338. Asia Pacific Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 339. Asia Pacific Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 340. Asia Pacific Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 341. China Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 342. China Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 343. China Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 344. Japan Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 345. Japan Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 346. Japan Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 347. India Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 348. India Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 349. India Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 350. South Korea Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 351. South Korea Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 352. South Korea Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 353. Taiwan Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 354. Taiwan Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 355. Taiwan Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 356. Australia Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 357. Australia Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 358. Australia Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 359. Rest of Asia-Pacific Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 360. Rest of Asia-Pacific Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 361. Rest of Asia-Pacific Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 362. Europe Gemcitabine Sales, by Country K Units (2025-2030)
  • Table 363. Europe Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 364. Europe Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 365. Europe Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 366. Germany Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 367. Germany Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 368. Germany Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 369. France Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 370. France Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 371. France Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 372. Italy Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 373. Italy Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 374. Italy Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 375. United Kingdom Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 376. United Kingdom Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 377. United Kingdom Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 378. Netherlands Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 379. Netherlands Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 380. Netherlands Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 381. Rest of Europe Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 382. Rest of Europe Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 383. Rest of Europe Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 384. MEA Gemcitabine Sales, by Country K Units (2025-2030)
  • Table 385. MEA Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 386. MEA Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 387. MEA Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 388. Middle East Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 389. Middle East Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 390. Middle East Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 391. Africa Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 392. Africa Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 393. Africa Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 394. North America Gemcitabine Sales, by Country K Units (2025-2030)
  • Table 395. North America Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 396. North America Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 397. North America Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 398. United States Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 399. United States Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 400. United States Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 401. Canada Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 402. Canada Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 403. Canada Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 404. Mexico Gemcitabine Sales, by Application K Units (2025-2030)
  • Table 405. Mexico Gemcitabine Sales, by Distribution Channel K Units (2025-2030)
  • Table 406. Mexico Gemcitabine Sales, by Dose of Gemcitabine K Units (2025-2030)
  • Table 407. Research Programs/Design for This Report
  • Table 408. Key Data Information from Secondary Sources
  • Table 409. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gemcitabine: by Application USD Million (2018-2023)
  • Figure 5. Global Gemcitabine: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Gemcitabine: by Dose of Gemcitabine USD Million (2018-2023)
  • Figure 7. South America Gemcitabine Share (%), by Country
  • Figure 8. Asia Pacific Gemcitabine Share (%), by Country
  • Figure 9. Europe Gemcitabine Share (%), by Country
  • Figure 10. MEA Gemcitabine Share (%), by Country
  • Figure 11. North America Gemcitabine Share (%), by Country
  • Figure 12. Global Gemcitabine: by Application K Units (2018-2023)
  • Figure 13. Global Gemcitabine: by Distribution Channel K Units (2018-2023)
  • Figure 14. Global Gemcitabine: by Dose of Gemcitabine K Units (2018-2023)
  • Figure 15. South America Gemcitabine Share (%), by Country
  • Figure 16. Asia Pacific Gemcitabine Share (%), by Country
  • Figure 17. Europe Gemcitabine Share (%), by Country
  • Figure 18. MEA Gemcitabine Share (%), by Country
  • Figure 19. North America Gemcitabine Share (%), by Country
  • Figure 20. Global Gemcitabine share by Players 2023 (%)
  • Figure 21. Global Gemcitabine share by Players (Top 3) 2023(%)
  • Figure 22. Global Gemcitabine share by Players (Top 5) 2023(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2023
  • Figure 26. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 27. Sun Pharma (India) Revenue: by Geography 2023
  • Figure 28. Tapi Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Tapi Teva (Israel) Revenue: by Geography 2023
  • Figure 30. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 32. Shanghai China Industrial Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 33. Shanghai China Industrial Co., Ltd (China) Revenue: by Geography 2023
  • Figure 34. Jinkang Pharmaceutical Technology (China) Revenue, Net Income and Gross profit
  • Figure 35. Jinkang Pharmaceutical Technology (China) Revenue: by Geography 2023
  • Figure 36. Fresenius Kabi Oncology Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. Fresenius Kabi Oncology Limited (India) Revenue: by Geography 2023
  • Figure 38. Arch Pharmalabs (India) Revenue, Net Income and Gross profit
  • Figure 39. Arch Pharmalabs (India) Revenue: by Geography 2023
  • Figure 40. Bharat Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 41. Bharat Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 42. Haisco Pharmaceutical Group (China) Revenue, Net Income and Gross profit
  • Figure 43. Haisco Pharmaceutical Group (China) Revenue: by Geography 2023
  • Figure 44. Global Gemcitabine: by Application USD Million (2025-2030)
  • Figure 45. Global Gemcitabine: by Distribution Channel USD Million (2025-2030)
  • Figure 46. Global Gemcitabine: by Dose of Gemcitabine USD Million (2025-2030)
  • Figure 47. South America Gemcitabine Share (%), by Country
  • Figure 48. Asia Pacific Gemcitabine Share (%), by Country
  • Figure 49. Europe Gemcitabine Share (%), by Country
  • Figure 50. MEA Gemcitabine Share (%), by Country
  • Figure 51. North America Gemcitabine Share (%), by Country
  • Figure 52. Global Gemcitabine: by Application K Units (2025-2030)
  • Figure 53. Global Gemcitabine: by Distribution Channel K Units (2025-2030)
  • Figure 54. Global Gemcitabine: by Dose of Gemcitabine K Units (2025-2030)
  • Figure 55. South America Gemcitabine Share (%), by Country
  • Figure 56. Asia Pacific Gemcitabine Share (%), by Country
  • Figure 57. Europe Gemcitabine Share (%), by Country
  • Figure 58. MEA Gemcitabine Share (%), by Country
  • Figure 59. North America Gemcitabine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Sun Pharma (India)
  • Tapi Teva (Israel)
  • Eli Lilly and Company (United States)
  • Shanghai China Industrial Co., Ltd (China)
  • Jinkang Pharmaceutical Technology (China)
  • Fresenius Kabi Oncology Limited (India)
  • Arch Pharmalabs (India)
  • Bharat Pharmaceuticals (India)
  • Haisco Pharmaceutical Group (China)
Additional players considered in the study are as follows:
Ningbo Menovo Pharmaceutical (China) , ScinoPharm (Taiwan) , HISUN USA, Inc. (United States) , Wuhu Huaren Science and Technology (China)
Select User Access Type

Key Highlights of Report


Mar 2024 211 Pages 86 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gemcitabine Market Quantitative research analysis
Global Gemcitabine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • High Cost of Drug Development

Know More About Global Gemcitabine Market Report?

Have a Query? Click Here

Other Related Reports

Antiplatelet Drugs Comprehensive Study by Application (Myocardial Infraction, Percutaneous Coronary Interventions, Angioplasty, Arterial Thrombosis, Dental surgeries, Others), Drug Type (Aspirin, Clo...
$ 3650
Lufenuron Comprehensive Study by Application (Fungal Infections, Ringworm, Agricultural Pesticide, Others), End (Dog, Cat, Other) Players and Region - Global Market Outlook to 2030
$ 3500
Tazarotene Comprehensive Study by Application (Psoriasis, Acne, Sun Damaged Skin, Others), Form (Cream, Gel, Foam), Distribution Channel (Online, Offline), Concentrations (0.05%, 0.1%) Players and Re...
$ 3500
Prenatal Vitamin Ingredient Comprehensive Study by Type (Vitamin, Calcium, Iron, Zinc, EPA/DHA, Magnesium, Others), Function (Neural & Brain Development, Gut Health, Bone Health, Nutrition, Weight Ma...
$ 3750
Coagulation Albumin Comprehensive Study by Type (Liquid, Powder, Frozen Plasma), Application (Infectious Hepatitis, Measles/Rubella, Fluid Therapy, Others), Albumin content (5%, 25%), End User (Pharm...
$ 3350
Dexmedetomidine Comprehensive Study by Type (0.004mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, Others), Application (Intensive Care Unit Sedation, Procedural Sedation, Others), Distribution Channel ...
$ 3500